Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: Association with liver histology

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 3, 2012, Pages 255-261

  Colak, Yasar ^a   Senates, Ebubekir ^b   Ozturk, Oguzhan ^a   Yilmaz, Yusuf ^c   Zemheri, Ebru ^a   Yilmaz Enc, Feruze ^a   Ulasoglu, Celal ^a   Aksaray, Sebahat ^b   Bozbeyoglu, Sabriye Gulcin ^a   Kiziltas, Safak ^a   Kurdas, Oya Ovunc ^b   Tuncer, Ilyas ^a  

^a GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

Fatty liver; insulin like growth factor binding protein 5; insulin like growth factor I

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR I; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84856722913     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834e8041     Document Type: Article

References (38)

1. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917-923. (Pubitemid 36397405)
2. Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis 2009; 13:249-266.
3. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern 1997; 126:137-145. (Pubitemid 27058588)
4. Adams LA, Lymp JF St, Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohortstudy. Gastroenterology 2005; 129:113-121. (Pubitemid 41002048)
5. Ekstedt M, Franzén LE, Mathiesen UL,Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865-873. (Pubitemid 46489550)
6. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36:1349-1354. (Pubitemid 35403524)
7. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51:1820-1832.
8. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47:455-460. (Pubitemid 351280713)
9. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18:1430-1437.
10. Yilmaz Y, Ulukaya E. Toward a biochemical diagnosis of NASH: insights from pathophysiology for distinguishing simple steatosis from steatohepatitis. Curr Med Chem 2011; 18:725-732.
11. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13:837-844. (Pubitemid 46470292)
12. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jørgensen T. Low serum insulin-like growth factor I is associated with increased riskof ischemic heart disease: a population-based case-control study. Circulation 2002; 106:939-944. (Pubitemid 34925327)
13. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004; 89:114-120. (Pubitemid 38183869)
14. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 1998; 18:277-282. (Pubitemid 28277606)
15. Saydah S, Ballard-Barbash R, Potischman N. Association of metabolic syndrome with insulin-like growth factors among adults in the US. Cancer Causes Control 2009; 20:1309-1316.
16. Ichikawa T, Nakao K, Hamasaki K, Furukawa R,Tsuruta S, Ueda Y, et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int 2007; 1:287-294.
17. Völzke H, Nauck M, Rettig R, Dörr M, Higham C, Brabant G, et al. Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur J Endocrinol 2009; 161:705-713.
18. Kim KS, Seu YB, Baek SH, Kim MJ, Kim KJ, Kim JH, et al. Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell 2007; 18:4543-4552.
19. Allan GJ, Beattie J, Flint DJ. Epithelial injury induces an innate repair mechanism linked to cellular senescence and fibrosis involving IGF-binding protein-5. J Endocrinol 2008; 199:155-164.
20. Fleming JM, Brandimarto JA, Cohick WS. The mitogen-activated protein kinase pathwaytonically inhibits both basal and IGF-I-stimulated IGF-binding protein-5 production in mammary epithelial cells. J Endocrinol 2007; 194:349-359. (Pubitemid 47249673)
21. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005; 166:399-407. (Pubitemid 40189037)
22. Yasuoka H, Jukic DM, Zhou Z, Choi AM, Feghali-Bostwick CA. Insulin-like growth factor binding protein 5 induces skin fibrosis: a novel murine model for dermal fibrosis. Arthritis Rheum 2006; 54:3001-3010. (Pubitemid 44497782)
23. Yasuoka H, Zhou Z, Pilewski JM, Oury TD, Choi AM, Feghali-Bostwick CA. Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol 2006; 169: 1633-1642. (Pubitemid 351181995)
24. Sokolović A, Sokolović M, Boers W, Elferink RP, Bosma PJ. Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair 2010; 3:3.
25. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438. (Pubitemid 38133916)
26. ACE/ADATask Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006; 29: 1955-1962.
27. Kleiner DE, Brunt EM,Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic steatohepatitis clinical research network: design and validation of a histological scoring system for nonalcoholicfatty liverdisease. Hepatology 2005; 41:1313-1321. (Pubitemid 40770284)
28. Sobrevals L, Rodriguez C, Romero-Trevejo JL, Gondi G, Monreal I, Pañeda A, et al. Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 2010; 51:912-921.
29. Anwar A, Zahid AA, Scheidegger KJ, Brink M, Delafontaine P. Tumor necrosis factor-alpha regulates insulin-like growth factor- 1 and insulin-like growth factor binding protein-3 expression in vascular smooth muscle. Circulation 2002; 105:1220-1225. (Pubitemid 34225824)
30. Lelbach A, Scharf JG, Ramadori G. Regulation of insulin-like growth factor-I and of insulin-like growth factor binding protein- 1, -3 and -4 in cocultures of rat hepatocytes and Kupffer cells by interleukin-6. J Hepatol 2001; 35:558-567. (Pubitemid 33078264)
31. Thissen JP,Verniers J. Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 1997; 138:1078-1084.
32. Canbay A, Higuchi H, Bronk SF,Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123:1323-1330.
33. Takehara T,Tatsumi T, Suzuki T, Rucker EB III, Hennighausen L, Jinushi M, et al. Hepatocyte-specific disruption of Bcl-x L leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004; 127:1189-1197. (Pubitemid 39345887)
34. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125:437-443. (Pubitemid 36929425)
35. Gressner AM. Liver fibrosis: perspectives in pathobiochemical research and clinical outlook. Eur J Clin Chem Clin Biochem 1991; 29:293-311.
36. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21:351-372. (Pubitemid 32923765)
37. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214:199-210. (Pubitemid 351160157)
38. Ikeda K, Wakahara T, Wang YQ, Kadoya H, Kawada N, Kaneda K. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 1999; 29:1760-1 767. (Pubitemid 29247050)